Metabolic effects of antihypertensive agents: Role of sympathoadrenal and renin-angiotensin systems

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 373, Issue 4, 2006, Pages 245-258

  Ernsberger, Paul ^a   Koletsky, Richard J ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin receptor antagonists; Cholesterol; Glucose; Hypertension; Insulin resistance; Obesity; Renin angiotensin system; Sympathetic nervous system; Triglycerides

Indexed keywords

ADRENALIN; ADRENERGIC RECEPTOR BLOCKING AGENT; ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPHEDRINE; FATTY ACID; GLUCOSE; HYDRALAZINE; IRBESARTAN; LIPID; METHYLDOPA; METOPROLOL; MOXONIDINE; NORADRENALIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENTERMINE; RAMIPRIL; SIBUTRAMINE; TELMISARTAN; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

ADRENERGIC SYSTEM; ANTIHYPERTENSIVE ACTIVITY; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG EFFECT; ESSENTIAL HYPERTENSION; EXERCISE INTOLERANCE; EXERCISE TOLERANCE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC SYNDROME X; NONHUMAN; OBESITY; ORTHOSTATIC HYPOTENSION; PATHOGENESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TACHYCARDIA; WEIGHT GAIN;

ANIMALS; ANTIHYPERTENSIVE AGENTS; GLUCOSE; HUMANS; LIPID METABOLISM; LIVER; METABOLIC SYNDROME X; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM;

EID: 33745683997     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-006-0080-3     Document Type: Review

References (158)

1. Ahren B, Lundquist I (1987) Alpha-adrenoceptor blockade by phentolamine inhibits beta-adrenergically and cholinergically induced glucagon secretion in the mouse. Horm Metab Res 19:600-603
2. Anichkov DA, Shostak NA, Schastnaya OV (2005) Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome. Curr Med Res Opin 21:113-119
3. Antonaccio MJ, High J, DeForrest JM, Sybertz E (1986) Antihypertensive effects of 12 beta adrenoceptor antagonists in conscious spontaneously hypertensive rats: relationship to changes in plasma renin activity, heart rate and sympathetic nerve function. J Pharmacol Exp Ther 238:378-387
4. Aoki VS, Brody MJ (1969) The effect of thiazide on the sympathetic nervous system of hypertensive rats. Arch Int Pharmacodyn Ther 177:423-434
5. Asai T, Kushiro T, Fujita H, Kanmatsuse K (2005) Different effects on inhibition of cardiac hypertrophy in spontaneously hypertensive rats by monotherapy and combination therapy of adrenergic receptor antagonists and/or the angiotensin II type 1 receptor blocker under comparable blood pressure reduction. Hypertens Res 28:79-87
6. Assimacopoulos-Jeannet FD, Blackmore PF, Exton JH (1982) Studies of the interaction between glucagon and alpha-adrenergic agonists in the control of hepatic glucose output. J Biol Chem 257:3759-3765
7. Barbieri C, Ferrari C, Caldara R, Testori G, Dal Bo GA, Bertazzoni A (1980) Clonidine-induced hyperglycemia: evidence against a growth hormone-mediated effect. J Pharmacol Exp Ther 214:433-436
8. Belahsen R, Deshaies Y (1993) Alpha-1 adrenergic blockade interacts with dietary carbohydrates on triacylglycerol metabolism in rats. J Nutr 123:520-528
9. Bernobich E, De Angelis L, Lerin C, Bellini G (2002) The role of the angiotensin system in cardiac glucose homeostasis: therapeutic implications. Drugs 62:1295-1314
10. Bjorkman O, Miles P, Wasserman D, Lickley L, Vranic M (1988) Regulation of glucose turnover during exercise in pancreatectomized, totally insulin-deficient dogs. Effects of beta-adrenergic blockade. J Clin Invest 81:1759-1767
11. Brandi LS, Santoro D, Natali A, Altomonte F, Baldi S, Frascerra S, Ferrannini E (1993) Insulin resistance of stress: sites and mechanisms. Clin Sci (Colch) 85:525-535
12. Bray GA (2002) Sibutramine and blood pressure: a therapeutic dilemma. J Hum Hypertens 16:1-3
13. Brors O, Lilleng R, Soyland K, Holm H (1987) Effect of acute potassium depletion and thiazide treatment on blood glucose in the normal rat. Res Commun Chem Pathol Pharmacol 58: 277-280
14. Bruss M, Bonisch H, Gothert M, Molderings GJ (2003) Molecular structure of the rabbit alpha(2A)-adrenoceptor: a contribution to the alpha(2A)- adrenoceptor versus I(1) imidazoline receptor controversy. N-S Arch Pharmacol 367:328-331
15. Carlsson PO, Berne C, Jansson L (1998) Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 41:127-133
16. Carmen GY, Victor SM (2006) Signalling mechanisms regulating lipolysis. Cell Signal 18:401-408
17. Chan SL, Mourtada M, Morgan NG (2001) Characterization of a KATP channel-independent pathway involved in potentiation of insulin secretion by efaroxan. Diabetes 50:340-347
18. Chu CA, Sindelar DK, Neal DW, Cherrington AD (1996) Direct effects of catecholamines on hepatic glucose production in conscious dog are due to glycogenolysis. Am J Physiol 271:
19. Chu CA, Sindelar DK, Neal DW, Allen EJ, Donahue EP, Cherrington AD (1997) Comparison of the direct and indirect effects of epinephrine on hepatic glucose production. J Clin Invest 99:1044-1056
20. Chu CA, Sindelar DK, Igawa K, Sherck S, Neal DW, Emshwiller M, Cherrington AD (2000) The direct effects of catecholamines on hepatic glucose production occur via alpha(1)- and beta(2)-receptors in the dog. Am J Physiol Endocrinol Metab 279: E463-E473
21. Chu KY, Lau T, Carlsson PO, Leung PS (2006) Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 55:367-374
22. Clasen R, Schupp M, Foryst-Ludwig A, Sprang C, Clemenz M, Krikov M, Thone-Reineke C, Unger T, Kintscher U (2005) PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 46:137-143
23. D'Eletto RD, Javitt NB (1989) Effect of doxazosin on cholesterol synthesis in cell culture. J Cardiovasc Pharmacol 13 Suppl 2:S1-S4
24. Daae LN, Westlie L (1998) A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk. Blood Press 7:39-45
25. Damas J, Garbacki N, Lefebvre PJ (2004) The kallikrein-kinin system, angiotensin converting enzyme inhibitors and insulin sensitivity. Diabetes Metab Res Rev 20:288-297
26. De Champlain J (2005) Do angiotensin II antagonists provide benefits beyond blood pressure reduction? Adv Ther 22:117-136
27. Del Rio G, Marrama P, Della C (1992) High urinary excretion of adrenaline in insulin dependent diabetic subjects. Horm Metab Res Suppl 26:106-108
28. De Luca N, Izzo R, Fontana D, Iovino G, Argenziano L, Vecchione C, Trimarco B (2000) Haemodynamic and metabolic effects of rilmenidine in hypertensive patients with metabolic syndrome X. A double-blind parallel study versus amlodipine. J Hypertens 18:1515-1522
29. Deshaies Y, Belahsen R (1993) Postprandial plasma triacylglycerols in rats under alpha 1-adrenergic blockade. Am J Physiol 264: E541-E547
30. Di Filippo C, Lampa E, Tufariello E, Petronella P, Freda F, Capuano A, D'Amico M (2005) Effects of irbesartan on the growth and differentiation of adipocytes in obese zucker rats. Obes Res 13:1909-1914
31. Ditullio NW, Cieslinski L, Matthews WD, Storer B (1984) Mechanisms involved in the hyperglycemic response induced by clonidine and other a2-adrenoceptor agonists. J Pharmacol Exp Ther 228:168-173
32. Efendic S, Efanov AM, Berggren PO, Zaitsev SV (2002) Two generations of insulinorropic imidazoline compounds. Diabetes 51 Suppl 3:S448-S454
33. Elfellah MS, Reid JL (1987) The role of skeletal muscle beta-adrenoreceptors in the regulation of plasma potassium. J Auton Pharmacol 7:175-184
34. Engeli S, Schling P, Gorzelniak K, Boschmann M, Janke J, Ailhaud G, Teboul M, Massiera F, Sharma AM (2003) The adipose-tissue renin-angiotensin- aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol 35:807-825
35. Erlich Y, Rosenthal T (1995) Effect of angiotensin-converting enzyme inhibitors on fructose induced hypertension and hyperinsulinaemia in rats. Clin Exp Pharmacol Physiol Suppl 22:8347-8349
36. Erlich Y, Rosenthal T (1998) Contribution of bradykinin to the beneficial effects of ramipril in the fructose-fed rat. J Cardiovasc Pharmacol 31:581-584
37. Ernsberger P, Koletsky RJ, Collins LA, Bedol DL (1996) Sympathetic nervous system in salt-sensitive and obese hypertension: Amelioration of multiple abnormalities by a central sympatholytic agent. Cardiovasc Drugs Ther 10:275-282
38. Ernsberger P, Friedman JE, Koletsky RJ (1997) The I(1)-imidazoline receptor: From binding site to therapeutic target in cardiovascular disease. J Hypertens 15 (Suppl. 1):S9-S23
39. Ernsberger P, Koletsky RJ, Friedman JE (1998) Contribution of sympathetic nervous system overactivity to cardiovascular and metabolic disease. Rev Contemp Pharmacother 9:411-428
40. Ernsberger P, Ishizuka T, Liu S, Farrell CJ, Bedol D, Koletsky RJ, Friedman JE (1999) Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB). J Pharmacol Exp Ther 288:139-147
41. Exton JH (1987) Mechanisms of hormonal regulation of hepatic glucose metabolism. Diabetes Metab Rev 3:163-183
42. Facchini FS, Stoohs RA, Reaven GM (1996) Enhanced sympathetic nervous system activity. The linchpin between insulin resistance, hyperinsulinemia, and heart rate. Am J Hypertens 9:1013-1017
43. Fink GD (1997) Long-term sympatho-excitatory effect of angiotensin II: a mechanism of spontaneous and renovascular hypertension. Clin Exp Pharmacol Physiol 24:91-95
44. Fisher SJ, Lekas MC, McCall RH, Shi ZQ, Giacca A, Vranic M (1996) Determinants of glucose turnover in the pathophysiology of diabetes: an in vivo analysis in diabetic dogs. Diabetes Metab 22:111-121
45. Friedman JE, Ishizuka T, Liu S, Farrell CJ, Koletsky RJ, Bedol D, Ernsberger P (1998) Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats. Blood Press Suppl 3:32-39
46. Furberg CD, Psaty BM, Pahor M, Alderman MH (2001) Clinical implications of recent findings from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) and other studies of hypertension. Ann Intern Med 135: 1074-1078
47. Giugliano D, Torella R, Cacciapuoti F, Gentile S, Verza M, Varricchio M (1980) Impairment of insulin secretion in man by nifedipine. Eur J Clin Pharmacol 18:395-398
48. Gletsu N, Doan TN, Cole J, Sutliff RL, Bernstein KE (2005) Angiotensin II-induced hypertension in mice caused an increase in insulin secretion. Vascul Pharmacol 42:83-92
49. Goyal RK (1999) Hyperinsulinemia and insulin resistance in hypertension: differential effects of antihypertensive agents. Clin Exp Hypertens 21:167-179
50. Granneman JG, Li P, Zhu Z, Lu Y (2005) Metabolic and cellular plasticity in white adipose tissue I: effects of beta3-adrenergic receptor activation. Am J Physiol Endocrinol Metab 289: E608-E616
51. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL (2000) Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 342:905-912
52. Guthrie GP Jr, Miller RE, Kotchen TA, Koenig SH (1983) Clonidine in patients with diabetes and mild hypertension. Clin Pharmacol Ther 34:713-717
53. Haenni A, Lithell H (1999) Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens 17 Suppl 3:S29-S35
54. Haffner SM (1997) Epidemiology of hypertension and insulin resistance syndrome. J Hypertens Suppl 15:S25-S30
55. Henriksen EJ, Jacob S (1995) Effects of captopril on glucose transport activity in skeletal muscle of obese Zucker rats. Metabolism 44:267-272
56. Hirose H, Maruyama H, Itoh K, Koyama K, Kido K, Saruta T (1992) Alpha-2 adrenergic agonism stimulates islet glucagon release from perfused rat pancreas: Possible involvement of alpha- 2A adrenergic receptor subtype. Acta Endocrinol (Copenh) 127: 279-283
57. Holtzman E, Rosenthal T, Goldbourt U, Segal P (1987) Do beta-blockers alter lipids and what are the consequences? J Cardiovasc Pharmacol 10 Suppl 2:S86-S92
58. Hsieh PS, Tai YH, Loh CH, Shih KC, Cheng WT, Chu CH (2005) Functional interaction of AT1 and AT2 receptors in fructose-induced insulin resistance and hypertension in rats. Metabolism 54:157-164
59. Iaccarino G, Trimarco V, Lanni F, Cipolletta E, Izzo R, Arcucci O, De Luca N, Di Renzo G (2005) beta-Blockade and increased dyslipidemia in patients bearing Glu27 variant of beta2 adrenergic receptor gene. Pharmacogenomics J 5:292-297
60. Izzo JL Jr, Black HR (2003) Hypertension Primer. Lippincott, Williams & Wilkins, Dallas
61. Jacob S, Balletshofer B, Henriksen EJ, Volk A, Mehnert B, Loblein K, Haring HU, Rett K (1999a) Beta-blocking agents in patients with insulin resistance: effects of vasodilating beta-blockers. Blood Press 8:261-268
62. Jacob S, Fogt DL, Dietze GJ, Henriksen EJ (1999b) The beta2-adrenergic modulator celiprolol reduces insulin resistance in obese Zucker rats. Life Sci 64:2071-2079
63. Jacob S, Klimm HJ, Rett K, Helsberg K, Haring HU, Godicke J (2004) Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 112:315-322
64. Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO (1993) Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 21:618-623
65. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME (2005) Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 23: 463-473
66. Jansen H, Lammers R, Baggen MG, Penders JM, Birkenhager JC (1989) Inhibition of hepatic cholesterol synthesis by the alpha 1-adrenoceptor blocker doxazosin in the hypercholesterolemic golden hamster. Life Sci 44:1013-1017
67. Julius S (1995) The defense reaction: A common denominator of coronary risk and blood pressure in neurogenic hypertension. Clin Exp Hypertens 17:375-386
68. Julius S (2000) Five decades of antihypertensive treatment: the unresolved issues. J Hypertens Suppl 18:S3-S7
69. Julius S, Gudbrandsson T, Jamerson K, Andersson O (1992) The interconnection between sympathetics, microcirculation, and insulin resistance in hypertension. Blood Press 1:9-19
70. Kakuta H, Sudoh K, Sasamata M, Yamagishi S (2005) Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 25:41-46
71. Kanatsuna T, Nakano K, Mori H, Kano Y, Nishioka H, Kajiyama S, Kitagawa Y, Yoshida T, Kondo M, Nakamura N (1985) Effects of nifedipine on insulin secretion and glucose metabolism in rats and in hypertensive type 2 (non-insulin dependent) diabetics. Arzneimittelforschung 35:514-517
72. Kawai Y, Arinze IJ (1983) beta-Adrenergic receptors in rabbit liver plasma membranes. Predominance of beta 2-receptors and mediation of adrenergic regulation of hepatic glycogenolysis. J Biol Chem 258:4364-4371
73. Keltikangas-Jarvinen L, Ravaja N, Raikkonen K, Lyytinen H (1996) Insulin resistance syndrome and autonomically mediated physiological responses to experimentally induced mental stress in adolescent boys. Metabolism 45:614-621
74. Kjeldsen SE, Rostrup M, Moan A, Mundal HH, Gjesdal K, Eide IK (1992) The sympathetic nervous system may modulate the metabolic cardiovascular syndrome in essential hypertension. J Cardiovasc Pharmacol 20 Suppl 8:S32-S39
75. Kjeldsen SE, Moan A, Petrin J, Weder AB, Julius S (1996) Effects of increased arterial epinephrine on insulin, glucose and phosphate. Blood Press 5:27-31
76. Klein C, Morton N, Kelley S, Metz S (1985) Transdermal clonidine therapy in elderly mild hypertensives: effects on blood pressure, plasma norepinephrine and fasting plasma glucose. J Hypertens Suppl 3:S81-S84
77. Koh KK, Quon MJ, Han SH, Chung WJ, Lee Y, Shin EK (2006) Antiinflammatory and metabolic effects of candesartan in hypertensive patients. Int J Cardiol 108:96-100
78. Koletsky RJ, Velliquette RA, Ernsberger P (2003) The role of I(1)-imidazoline receptors and alpha(2)-adrenergic receptors in the modulation of glucose and lipid metabolism in the SHROB model of metabolic syndrome X. Ann N Y Acad Sci 1009:251-261
79. Kulcsar-Gergely J, Posan E, Kulcsar A (1994) Metabolic actions of a single atenolol and metoprolol dose. Arzneimittelforschung 44:1183-1185
80. Kurtz TW (2005) Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol 42 Suppl 1:S9-S16
81. Kurtz TW, Pravenec M (2004) Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens 22:2253-2261
82. Lacey RJ, Berrow NS, Scarpello JH, Morgan NG (1991) Selective stimulation of glucagon secretion by beta 2-adrenoceptors in isolated islets of Langerhans of the rat. Br J Pharmacol 103:1824-1828
83. Lacey RJ, Chan SLF, Cable HC, James RFL, Perrett CW, Scarpello JHB, Morgan NG (1996) Expression of a2- and b-adrenoceptor subtypes in human islets of Langerhans. J Endocrinol 148:531-543
84. Lee AD, Hansen PA, Schluter J, Gulve EA, Gao J, Holloszy JO (1997) Effects of epinephrine on insulin-stimulated glucose uptake and GLUT-4 phosphorylation in muscle. Am J Physiol 273:C1082-C1087
85. Leineweber K, Buscher R, Bruck H, Brodde OE (2004) Beta-adrenoceptor polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 369:1-22
86. Leung PS, Carlsson PO (2005) Pancreatic islet renin angiotensin system: its novel roles in islet function and in diabetes mellitus. Pancreas 30:293-298
87. Li Y-Q, Ji H, Ding DY, Ye XL (2006) Metabolic effects of telmisartan in spontaneously hypertensive rats. Naunyn-Schmiedeberg's Archives of Pharmacology DOI 10.1007/s00210-006-0069-y
88. Lind L, Berne C, Pollare T, Lithell H (1995) Metabolic effects of antihypertensive treatment with nifedipine or furosemide: a double-blind, cross-over study. J Hum Hypertens 9:137-141
89. Lithell H (1992) Insulin resistance and cardiovascular drugs. Clin Exp Hypertens A 14:151-162
90. Liu YL, Toubro S, Astrup A, Stock MJ (1995) Contribution of beta 3-adrenoceptor activation to ephedrine-induced thermogenesis in humans. Int J Obes Relat Metab Disord 19:678-685
91. Ljung B, Ablad B, Drews L, Fellenius E, Kjellstedt A, Wallborg M (1976) Anti-hypertensive effect of metoprolol in spontaneously hypertensive rats. Clin Sci Mol Med Suppl 3:443S-445S
92. Lorrain J, Angel I, Duval N, Eon MT, Oblin A, Langer SZ (1992) Adrenergic and nonadrenergic cotransmitters inhibit insulin secretion during sympathetic stimulation in dogs. Am J Physiol 263:E72-E78
93. Lumb PJ, McMahon Z, Chik G, Wierzbicki AS (2004) Effect of moxonidine on lipid subfractions in patients with hypertension. Int J Clin Pract 58:465-468
94. Mackintosh VS, Elsegood CL, Redgrave TG (1991) Effects of adrenoreceptor antagonists and agonists on clearance of emulsion models of triacylglycerol-rich lipoproteins from plasma in rats. Clin Exp Pharmacol Physiol 18:775-788
95. Mancia G, Brown M, Castaigne A, de Leeuw P, Palmer CR, Rosenthal T, Wagener G, Ruilope LM (2003) Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 41:431-436
96. Mancia G, Dell'oro R, Quarti-Trevano F, Scopelliti F, Grassi G (2006) Angiotensin-sympathetic system interactions in cardiovascular and metabolic disease. J Hypertens 24 Suppl 1:S51-S56
97. Masuo K, Mikami H, Ogihara T, Tuck ML (1997) Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population. Am J Hypertens 10:77-83
98. McKenney JM, Goodman RP, Wright JT Jr (1985) Use of antihypertensive agents in patients with glucose intolerance. Clin Pharm 4:649-656
99. Mervaala EM, Teravainen TL, Malmberg L, Laakso J, Vapaatalo H, Karppanen H (1997) Cardiovascular effects of a low-dose combination of ramipril and felodipine in spontaneously hypertensive rats. Br J Pharmacol 121:503-510
100. Metz SA, Halter JB, Robertson RP (1978) Induction of defective insulin secretion and impaired glucose tolerance by clonidine: Selective stimulation of metabolic α-adrenergic pathways. Diabetes 27:554-562
101. Moratinos J, Reverte M (1993) Effects of catecholamines on plasma potassium: the role of alpha- and beta-adrenoceptors. Fundam Clin Pharmacol 7:143-153
102. Morgan NG, Exton JH, Blackmore PF (1983) Angiotensin II inhibits hepatic cAMP accumulation induced by glucagon and epinephrine and their metabolic effects. FEBS Lett 153:77-80
103. Moser M (1998) Why are physicians not prescribing diuretics more frequently in the management of hypertension? J Am Med Assoc 279:1813-1816
104. Murray DP, Watson RD, Zezulka AV, Murray RG, Littler WA (1988) Plasma catecholamine levels in acute myocardial infarction: influence of beta-adrenergic blockade and relation to central hemodynamics. Am Heart J 115:38-44
105. Navarro-Cid J, Maeso R, Perez-Vizcaino F, Casal MC, Cachofeiro V, Ruilope LM, Tamargo J, Lahera V (1996) Effects of antihypertensive drugs on blood pressure and metabolic alterations in the fructose-induced hypertensive rat. Am J Hypertens 9:669-674
106. Nevzorova J, Evans BA, Bengtsson T, Summers RJ (2006) Multiple signalling pathways involved in beta2-adrenoceptor-mediated glucose uptake in rat skeletal muscle cells. Br J Pharmacol 147:446-454
107. Nonogaki K (2000) New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia 43:533-549
108. Nonogaki K, Iguchi A (1997) Role of central neural mechanisms in the regulation of hepatic glucose metabolism. Life Sci 60:797-807
109. Nonogaki K, Moser AH, Feingold KR, Grunfeld C (1994) Alpha-adrenergic receptors mediate the hypertriglyceridemia induced by endotoxin, but not tumor necrosis factor, in rats. Endocrinology 135:2644-2650
110. Olubadewo JO, Heimberg M (1993) Effects of adrenergic agonists and antagonists on the metabolism of [1-14C]oleic acid by rat hepatocytes. Biochem Pharmacol 45:2441-2447
111. Opie LH, Schall R (2004) Old antihypertensives and new diabetes. J Hypertens 22:1453-1458
112. Ostlund-Lindqvist AM, Eklund A, Sjoblom L, Jonsson L (1989) Effect of metoprolol on plasma lipids and arterial intimal lipid deposition in spontaneously hypertensive rats. Atherosclerosis 80:135-142
113. Paquot N, Schneiter P, Jequier E, Tappy L (1995) Effects of glucocorticoids and sympathomimetic agents on basal and insulin-stimulated glucose metabolism. Clin Physiol 15:231-240
114. Park SC, Radin MJ, Hoepf T, McCune SA (1999) Comparison of verapamil and felodipine treatment on lipid and glucose metabolism in obese female SHHF/Mcc-facp rats. Proc Soc Exp Biol Med 221:224-233
115. Pelleg A, Katchanov G, Xu J (1997) Autonomie neural control of cardiac function: modulation by adenosine and adenosine 5′-triphosphate. American Journal of Cardiology 79:11-14
116. Penicaud L, Berthault MF, Morin J, Dubar M, Ktorza A, Ferre P (1998) Rilmenidine normalizes fructose-induced insulin resistance and hypertension in rats. J Hypertens Suppl 16:S45-S49
117. Pitre M, Gaudreault N, Santure M, Nadeau A, Bachelard H (1999) Isradipine and insulin sensitivity in hypertensive rats. Am J Physiol 276:E1038-E1048
118. Ramracheya RD, Muller DS, Wu Y, Whitehouse BJ, Huang GC, Amiel SA, Karalliedde J, Viberti G, Jones PM, Persaud SJ (2006) Direct regulation of insulin secretion by angiotensin II in human islets of Langerhans. Diabetologia 49:321-331
119. Ran J, Hirano T, Adachi M (2004) Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. Am J Physiol Endocrinol Metab 287:E227-E232
120. Ran J, Hirano T, Fukui T, Saito K, Kageyama H, Okada K, Adachi M (2006) Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance. Metabolism 55: 478-488
121. Randle PJ (1998) Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev 14:263-283
122. Randle PJ, Garland PB, Newsholme EA, Hales CN (1965) The glucose fatty acid cycle in obesity and maturity onset diabetes mellitus. Ann N Y Acad Sci 131:324-333
123. Reaven GM (1993) Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 44:121-131
124. Reaven GM, Lithell H, Landsberg L (1996) Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med 334:374-381
125. Reinhart PH, Taylor WM, Bygrave FL (1982) Studies on alpha-adrenergic- induced respiration and glycogenolysis in perfused rat liver. J Biol Chem 257:1906-1912
126. Rodrigues B, Grassby PF, Battell ML, Lee SY, McNeill JH (1994) Hypertriglyceridemia in experimental diabetes: relationship to cardiac dysfunction. Can J Physiol Pharmacol 72:447-455
127. Rosen SG, Clutter WE, Shah SD, Miller JP, Bier DM, Cryer PE (1983) Direct alpha-adrenergic stimulation of hepatic glucose production in human subjects. Am J Physiol 245:E616-E626
128. Rosen P, Ohly P, Gleichmann H (1997) Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructose-fed rat. J Hypertens 15(Suppl. 1):S31-S38
129. Ruffolo RR, Jr, Nichols AJ, Hieble JP (1991) Metabolic regulation by a1- and a2-adrenoceptors. Life Sci 49:171-183
130. Salem HA, Abdel Rahman MS, Dahab GM (1993) Influence of diltiazem and/or propranolol on rat blood glucose levels in normal and diabetic animals. J Appl Toxicol 13:85-89
131. Schupp M, Janke J, Clasen R, Unger T, Kintscher U (2004) Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109:2054-2057
132. Sechi LA, Catena C, Zingaro L, De Carli S, Bartoli E (1997) Hypertension and abnormalities of carbohydrate metabolism possible role of the sympathetic nervous system. Am J Hypertens 10:678-682
133. Semple CG, Smith M, Furman BL (1988) Inhibition of glucose-induced insulin secretion by calcium channel blocking drugs invitro but not in-vivo in the rat. J Pharm Pharmacol 40:22-26
134. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC (2002) Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 40:609-611
135. Sica DA (2004) Diuretic-related side effects: development and treatment. J Clin Hypertens (Greenwich) 6:532-540
136. Szabo B (2002) Imidazoline antihypertensive drugs: a critical review on their mechanism of action. Pharmacol Ther 93:1-35
137. Tahmasebi M, Puddefoot JR, Inwang ER, Vinson GP (1999) The tissue renin-angiotensin system in human pancreas. J Endocrinol 161:317-322
138. Tavernier G, Barbe P, Galitzky J, Berlan M, Caput D, Lafontan M, Langin D (1996) Expression of b3-adrenoceptors with low lipolytic action in human subcutaneous white adipocytes. J Lipid Res 37:87-97
139. Toda N (2003) Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther 100:215-234
140. Tolentino-Silva FP, Haxhiu MA, Waldbaum S, Dreshaj IA, Ernsberger P (2000) alpha(2)-adrenergic receptors are not required for central anti-hypertensive action of moxonidine in mice. Brain Res 862:26-35
141. Tomiyama H, Kushiro T, Abeta H, Ishii T, Takahashi A, Furukawa L, Asagami T, Hino T, Saito F, Otsuka Y (1994) Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor. Hypertension 23:450-455
142. Trost BN, Weidmann P (1988) Metabolic effects of calcium antagonists in humans, with emphasis on carbohydrate, lipid, potassium, and uric acid homeostases. J Cardiovasc Pharmacol 12 Suppl 6:S86-S92
143. Ura N, Higashiura K, Shimamoto K (1999) The mechanisms of insulin sensitivity improving effects of angiotensin converting enzyme inhibitor. Immunopharmacology 44:153-159
144. Velasco M, Silva H, Feldstein E, Pellicer R, Morillo J, Urbina-Quintana A, Hernandez-Pieretti O (1985) Effects of prazosin and alphamethyldopa on blood lipids and lipoproteins in hypertensive patients. Eur J Clin Pharmacol 28:513-516
145. Velliquette RA, Ernsberger P (2003a) Contrasting metabolic effects of antihypertensive agents. J Pharmacol Exp Ther 307:1104-1111
146. Velliquette RA, Ernsberger P (2003b) The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X. J Pharmacol Exp Ther 306:646-657
147. Velliquette RA, Kossover R, Previs SF, Ernsberger P (2006) Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X. Naunyn-Schmiedeberg's Arch Pharmacol 372:300-312
148. Verma S, Bhanot S, Hicke A, McNeill JH (1997) Chronic T-type Ca2+ channel blockade with mibefradil in hyperinsulinemic, insulin-resistant and hypertensive rats. Cardiovasc Res 34: 121-128
149. Webster WB Jr, McConnaughey MM (1982) Clonidine and glucose intolerance. Drug Intell Clin Pharm 16:325-328
150. Whelton PK, Barzilay J, Cushman WC, Davis BR, Iiamathi E, Kostis JB, Leenen FH, Louis GT, Margolis KL, Mathis DE, Moloo J, Nwachuku C, Panebianco D, Parish DC, Pressel S, Simmons DL, Thadani U (2005) Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 165:1401-1409
151. Williams PT, Haskell WL, Vranizan KM, Krauss RM (1995) The associations of high-density lipoprotein subclasses with insulin and glucose levels, physical activity, resting heart rate, and regional adiposity in men with coronary artery disease: The Stanford Coronary Risk Intervention Project Baseline Survey. Metabolism 44:106-114
152. Yakubu-Madus FE, Johnson WT, Zimmerman KM, Dananberg J, Steinberg MI (1999) Metabolic and hemodynamic effects of moxonidine in the Zucker diabetic fatty rat model of type 2 diabetes. Diabetes 48:1093-1100
153. Yamauchi T, Iwai M, Kobayashi N, Shimazu T (1998) Noradrenaline and ATP decrease the secretion of triglyceride and apoprotein B from perfused rat liver. Pflugers Arch 435:368-374
154. Yenicesu M, Yilmaz MI, Caglar K, Sonmez A, Eyileten T, Acikel C, Kilic S, Bingol N, Bingol S, Vural A (2005) Blockade of the renin-angiotensin system increases plasma adiponectin levels in type-2 diabetic patients with proteinuria. Nephron Clin Pract 99: c115-c121
155. Yorek MA, Rufo GA Jr, Ray PD (1980) Gluconeogenesis in rabbit liver. III. The influences of glucagon, epinephrine, alpha- and beta-adrenergic agents on gluconeogenesis in isolated hepatocytes. Biochim Biophys Acta 632:517-526
156. Yvan-Charvet L, Even P, Bloch-Faure M, Guerre-Millo M, Moustaid-Moussa N, Ferre P, Quignard-Boulange A (2005) Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes 54:991-999
157. Zaitsev SV, Efanov AM, Efanova IB, Larsson O, Östenson CG, Gold G, Berggren PO, Efendic S (1996) Imidazoline compounds stimulate insulin release by inhibition of KATP channels and interaction with the exocytotic machinery. Diabetes 45:1610-1618
158. Zhu QM, Lesnick JD, Jasper JR, MacLennan SJ, Dillon MP, Eglen RM, Blue DR Jr (1999) Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice. Br J Pharmacol 126:1522-1530